Read more
4:35 PM · 12 October 2021

CureVac stops development of its COVID-19 vaccine

CureVac
Stocks
CVAC.US, CureVac N.V.
-
-

CureVac (CVAC.US) stock fell sharply during today's session, after the biopharmaceutical company abandoned efforts to get its first generation drug approved by regulators. The decision came after the European Medicines Agency told the company it would not fast-track the approval process after clinical tests had shown it had only a 48% efficiency rate in preventing serious disease. CureVac plans to now focus on the development of second-generation COVID-19 vaccine candidates with its partner GlaxoSmithKline (GSK.US). CureVac and GSK aim to secure regulatory approval for market readiness of an improved Covid-19 vaccine in 2022. The companies also plan to accelerate efforts to progress the development of modified mRNA vaccine constructs.

CureVac (CVAC.US) stock launched today's session sharply lower, however buyers managed to partially erase early losses. However, only breaking above the resistance at $42.58 will invalidate the bearish scenario and the stock price may launch another upward impulse towards $52.85. Source: xStation5

10 December 2025, 3:30 PM

Ferrari shares near 2-year lows 📉

10 December 2025, 3:01 PM

Photronics shares surge almost 50% on strong Q3 earnings report 📈

10 December 2025, 1:24 PM

Nvidia gains slightly on potential ByteDance and Alibaba orders 📈

10 December 2025, 11:41 AM

A New Era for Nvidia’s Chips: More Security, More Tension

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits